DreamPharm Products:
Lutein-20||Herbs for headache, fever, and migraine ||
Milk thistle||Saw palmetto||
Triple B Super Vision||Garlic, Ginger, and Grapeseed Extract||
Ginseng and Ginkgo||Hair Million||
DHEA||Coenzyme Q10||
Sleep Aid herbal formula - natural sleep aid||Herbal Breath - herbs for bad breath problems.||
Weight loss herbal formula for menopause and pms||Ginkgo biloba||
Colon cleansing, Laxative||ViaVita, Lecithin for healthy liver
Fatty acids resources:
Pathogen research abs 1 || Pathogen research abs 2 || Pathogen research abs 3 || Pathogen research abs 4 || Pathogen research abs 5 ||
Hormone and endocrine research abs 1 || Hormone and endocrine research abs 2 || Hormone and endocrine research abs 3 || Hormone and endocrine research abs 4 || Hormone and endocrine research abs 5
|| Follicle and follicular cells research abs 1
|| Interferon research abs 1
|| Hemoglobin research abs
|| Stem cell research abs
|| Nucleic acid research abs
|| Herpes research abs
|| Bronchitis research abs
J Antimicrob Chemother. 1999 Mar;43 Suppl A:107-13.
Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
Destache CJ, Dewan N, O'Donohue WJ, Campbell JC, Angelillo VA.
School of Pharmacy & Allied Health Professions, Creighton University, Omaha, NE 68178, USA. CDestacreighton.edu
Limited data exist to guide physicians in the cost-effective treatment of acute exacerbation of chronic bronchitis (AECB). Therefore, the main objective of this study was to determine the antimicrobial efficacy and related costs for patients with AECB. A retrospective review of 60 outpatient medical records with a diagnosis of chronic obstructive pulmonary disease (COPD) and chronic bronchitis episodes from a pulmonary clinic of a teaching institution was undertaken. The participating patients had a total of 224 episodes of AECB requiring antibiotic treatment. Before review, empirical antibiotic choices were divided into first-line (amoxycillin, co-trimoxazole, tetracyclines, erythromycin), second-line (cephradine, cefuroxime, cefaclor, cefprozil) and third-line (co-amoxiclav, azithromycin, ciprofloxacin) agents. Patients receiving first-line agents failed significantly more frequently than third-line agents (19% vs 7%, P < 0.05). Additionally, patients prescribed first-line agents were hospitalized significantly more often for AECB within 2 weeks of outpatient treatment as compared with patients prescribed third-line agents (18.0% vs 5.3% third-line agents; P < 0.02). Time between subsequent AECB episodes requiring treatment was significantly longer for patients receiving third-line agents compared with first-line and second-line agents (P < 0.005). Pharmacy costs were lowest with first-line agents (first-line US$10.30 +/- 8.76; second-line US$24.45 +/- 25.65; third-line US$45.40 +/- 11.11; P < 0.0001), but third-line agents showed a trend towards lower mean total costs of AECB treatment (first-line US$942 +/- 2173; second-line, US$563 +/- 2296; third-line, US$542 +/- 1946). The use of third-line antimicrobials, co-amoxiclav, ciprofloxacin or azithromycin, significantly reduced the failure rate and need for hospitalization, prolonged the time between AECB episodes, and showed a lower total cost for the management of AECB. Prospective studies are needed to confirm these findings.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10225580&dopt=Abstract
Int J Infect Dis. 2003 Mar;7 Suppl 1:S005-10.
Why do we need to eradicate pathogens in respiratory tract infections?
Garau J.
Department of Medicine, Hospital Mutua de Terrassa, Barcelona, Spain.
Evidence from studies in otitis media, acute bacterial sinusitis and acute exacerbations of chronic bronchitis indicate that clinical efficacy is dependent on bacterial eradication. Failure to eradicate bacterial pathogens increases the potential for clinical failure, incurring further costs, and may also select and maintain bacteria that are resistant to a wide range of antimicrobials. Bacteriologically confirmed clinical failures have been reported in pneumococcal pneumonia with both macrolides and older fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin). These failures were due to the involvement of resistant pathogens (macrolides) or suboptimal pharmacokinetics/pharmacodynamics (PK/PD) (quinolones). However, persistent positive blood cultures have not been reported during therapy with adequate doses of benzylpenicillins or aminopenicillins. Treatment failure, driven by the failure to eradicate pathogens, leads to both economic and environmental costs, hospitalization being the major cost driver. Failure to achieve bacterial eradication may also lead to the development and spread of resistance. Different types of antimicrobials appear to be driving resistance to different extents, and this may be due to suboptimal PK/PD. In conclusion, factors to consider when prescribing include an accurate diagnosis, knowledge of local epidemiology, the role of PK/PD principles in antimicrobial choice, clinical outcomes in relation to bacteriologic efficacy, and resistance and its bacteriologic and clinical impact. The vicious cycle of infection, inappropriate therapy, bacteriologic failure, selection/spread of resistance and further infection needs to be broken by the use of appropriate treatments to achieve bacterial eradication.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12839702&dopt=Abstract [PubMed - in process]
Manag Care Interface. 2003 Jun;16(6):34-40, 55.
Costs of broad-spectrum antibiotic use for acute sinusitis, chronic bronchitis, and pneumonia in a managed care population.
Coughlin CM, Nelson M, Merchant S, Gondek K.
Economic and Outcomes Research, Ingenix, Inc., Eden Prairie, Minnesota, USA.
Respiratory infections place a heavy burden on patients, providers, employers, and health care systems. The prescribing of antibiotics is common, despite the fact that many respiratory conditions are caused by viruses. The economic effect of treating respiratory tract infections with broad-spectrum antibiotics was retrospectively analyzed by means of health care claims data from six managed care health plans affiliated with a large national insurer. A regression model was used to adjust for factors that can influence treatment costs, such as age, baseline cost, retreatment, and drug cost. The costs of treating chronic bronchitis, pneumonia, and acute sinusitis with moxifloxacin, gatifloxacin and nonfluoroquinolone broad-spectrum agents were significantly lower than the costs associated with levofloxacin treatment.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12841074&dopt=Abstract
Rev Mal Respir. 2003 Apr;20(2 Pt 1):267-71.
[Anthracotic bronchitis and pulmonary mica overload]
[Article in French]
Mulliez P, Billon-Galland MA, Dansin E, Janson X, Plisson JP.
Service de Pneumologie, Hopital Saint Philibert, 59462 Lomme Cedex, France. mulliez.philipphicl.fupl.asso.fr
INTRODUCTION: The discovery of anthracotic plaques generally suggests either a history of tuberculosis or occupational exposure to dust. Other etiologies should, however, be considered. CASE REPORTS: A 60-year-old Iranian woman presented with a history of dyspnoea and with chest radiography demonstrating calcified hilar lymph nodes and interstitial lung disease. Pulmonary function tests revealed airway obstruction. A diffuse bronchial inflammatory appearance accompanied by anthracotic plaques was found at bronchoscopy, which prompted transmission electron microscopy analysis of non-fibrous mineral particles in the bronchoalveolar lavage fluid (BALF). This demonstrated the presence of an alveolar particle count greater than 10(7) particles/ml (p/ml), significantly more than that found in 42 BALF samples taken from controls without a history of occupational dust exposure (4,4.10(5) p/ml). Furthermore, the analysis also revealed an abnormally elevated proportion of mica particles (64%). Two other individuals, a 68 year-old Moroccan woman and a 70-year-old Algerian woman, who had anthracotic plaques, but no radiological evidence of interstitial lung disease, also underwent mineral analysis of BALF. Neither were found to have a raised alveolar particle count, but the mineral profile showed an abnormally elevated proportion of micas (62%) for one patient, and silica crystalline (40%) as well as micas (32%) for the other patient. CONCLUSIONS: Even if mica is present in 30 to 90% of the BALF, the results observed in these three patients raises the possibility of non-occupational environmental exposure and that anthracotic plaques might be associated with domestic pollution.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12844024&dopt=Abstract [PubMed - in process]
Concerned about losing hair? Hair loss and baldness is indeed a visible problem, and
could be more than just the matter of change in appearance.
Saw palmetto berry is a widely known herbal supplement for hair loss problems.
However, there are a number of great anecdotal herbs that people used for thousands of years stop hair loss and
start hair growth.
Numerous anecdotal cases have demonstrated that this herbal formula based on Chinese herbs actually improves the age-related hair thinning and hair loss
for a significant fraction of people who take it diligently. It is unknown how Hair Million herbs actually stop hair loss, and promote hair growth,
No scientific research or placebo controlled clinical trials have been conducted. Nonetheless, a number of people agree that it works.
DreamPharm Online Healthy Supplements ||
Lutein ||
Progesterone Cream ||
Natural herbal formula for hair loss problems ||